This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial

Authors

Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R., Watkins, W. E., Xu, Y., Murthy, A. K.

Journal

Neurology, Volume: 72, No.: 18, Pages.: 1555-1561

Year of Publication

2009

Abstract

Background: Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.; Methods: In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks) or placebo treatment. Primary efficacy variables included change from baseline in the modified Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-Cog) and Clinical Dementia Rating Scale-sum of boxes (CDR-SB) after 48 weeks of treatment (modified intention-to-treat analysis). Secondary efficacy measures evaluated cognition, behavior, and function.; Results: The dual primary efficacy endpoint was not reached. We noted a small, but significant, decrease in modified ADAS-Cog scores in favor of donepezil at study endpoint. Little change from baseline in CDR-SB and secondary variables was observed for either group. Patient Global Assessment scores favored donepezil at all time points except week 12 (p < or = 0.05). Perceived Deficits Questionnaire scores favored donepezil at week 24 (p = 0.05). Clinical Global Impression of Change-MCI scores favored donepezil only at week 6 (p = 0.04). Adverse events were generally mild or moderate. More donepezil-treated subjects (18.4%) discontinued treatment due to adverse events than placebo-treated subjects (8.3%).; Conclusions: Donepezil demonstrated small but significant improvement on the primary measure of cognition but there was no change on the primary measure of global function. Most other measures of global impairment, cognition, and function were not improved, possibly because these measures are insensitive to change in MCI. Responses on subjective measures suggest subjects perceived benefits with donepezil treatment.;

Bibtex Citation

@article{Doody_2009, doi = {10.1212/01.wnl.0000344650.95823.03}, url = {http://dx.doi.org/10.1212/01.wnl.0000344650.95823.03}, year = 2009, month = {jan}, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {72}, number = {18}, pages = {1555--1561}, author = {R. S. Doody and S. H. Ferris and S. Salloway and Y. Sun and R. Goldman and W. E. Watkins and Y. Xu and A. K. Murthy}, title = {Donepezil treatment of patients with {MCI}: A 48-week randomized, placebo-controlled trial}, journal = {Neurology} }

Keywords

administration & dosage, adverse effects, aged, aged, 80 and over, alzheimer disease, cholinesterase inhibitors, cognition disorders, disease progression, donezepil, double-blind method, drug therapy, endpoint determination, female, humans, indans, male, methods, middle aged, neuropsychological tests, outcome assessment (health care), patient compliance, physiopathology, piperidines, prevention & control, psychology, severity of illness index, statistics & numerical data, treatment outcome

Countries of Study

USA

Types of Dementia

Mild Cognitive Impairment (MCI)

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime